Schonfeld Strategic Advisors’s Anavex Life Sciences AVXL Stock Holding History

Schonfeld Strategic Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$71.4K	Buy	+27,577	New	+$81.6K	﹤0.01%	2340
2026 Q1	–	Sell	-46,195	Closed	-$164K	–	2216
2025 Q4	$164K	Buy	+46,195	New	+$283K	﹤0.01%	1748
2023 Q4	–	Sell	-26,287	Closed	-$172K	–	1869
2023 Q3	$172K	Buy	26,287 +10,604	+68%	+$84.4K	﹤0.01%	1438
2023 Q2	$128K	Buy	+15,683	New	+$134K	﹤0.01%	1675
2022 Q4	–	Sell	-93,045	Closed	-$960K	–	2584
2022 Q3	$960K	Buy	93,045 +76,246	+454%	+$805K	0.01%	1298
2022 Q2	$168K	Buy	+16,799	New	+$159K	﹤0.01%	1963

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Schonfeld Strategic Advisors's AVXL Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in Anavex Life Sciences (AVXL) in Q2 2026: 27,577 shares worth $71.4K. The stake represents ﹤0.01% of the portfolio and ranks #2340 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in AVXL as recently as Q4 2025.

Schonfeld Strategic Advisors first reported a position in AVXL in Q2 2022 and has held it in 6 quarters since. The position peaked at $960K in Q3 2022. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

Schonfeld Strategic Advisors held 27,577 shares of Anavex Life Sciences worth $71.4K as of Q2 2026.
Anavex Life Sciences was a new Schonfeld Strategic Advisors position in Q2 2026.
Anavex Life Sciences made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #2340 holding.
Schonfeld Strategic Advisors first reported a position in Anavex Life Sciences in Q2 2022 and has held it in 6 quarters since.
Schonfeld Strategic Advisors's Anavex Life Sciences position peaked at $960K in Q3 2022.
179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.